Floatz logo

Inv-8989

Advance Solid Tumors

Shenzhen Ionova Life Sciences Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Advance Solid Tumors cohort.

Asset / SponsorPhaseRating
Carboplatin
Sanofi
Phase 1CC
Iniparib
Sanofi
Phase 1CC
Alk-N001 For
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1CC
Kivu-107
Kivu Bioscience Inc.
Phase 1CC

Same molecule, other indications

Inv-8989 is also rated in:

pancreatic adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
biliary tract cancerDormant
CCC
Indicative ·
48 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →